Medicus Pharma Ltd (NASDAQ:MDCX) Given Average Rating of “Moderate Buy” by Analysts

Medicus Pharma Ltd (NASDAQ:MDCX) has earned an average recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $23.50.

A number of research firms have issued reports on MDCX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Medicus Pharma in a report on Monday, December 15th.

Institutional Investors Weigh In On Medicus Pharma

Hedge funds have recently made changes to their positions in the business. Private Advisor Group LLC boosted its position in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after buying an additional 5,500 shares during the period. Osaic Holdings Inc. raised its stake in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after acquiring an additional 9,000 shares in the last quarter. Jane Street Group LLC acquired a new position in Medicus Pharma during the 2nd quarter worth $41,000. Brave Asset Management Inc. acquired a new position in Medicus Pharma during the 3rd quarter worth $46,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Medicus Pharma in the third quarter worth $59,000.

Medicus Pharma Trading Up 2.2%

NASDAQ:MDCX opened at $1.37 on Tuesday. The stock has a 50 day moving average of $1.73 and a 200-day moving average of $2.18. The firm has a market capitalization of $34.40 million, a PE ratio of -0.64 and a beta of -1.12. Medicus Pharma has a 52 week low of $1.28 and a 52 week high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). As a group, analysts predict that Medicus Pharma will post -1.14 EPS for the current fiscal year.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.